ICICI Venture has acquired majority control in US-based clinical research company Radiant Research for an undisclosed amount, as reported by Economic Times.
Last year Radiant Research had sold a part of its clinical research business, constituting eight clinical pharmacology centres, to US-based clinical research company Covance for $65 million. With 26 other clinical centres, the current deal could have been valued at $150 million plus.
Apart from clinical centres, Radiant compromises of a full service CRO and a centralised patient recruitment company, employing over 400 clinical research professionals. Radiant Research had clocked revenues of $73.5 million in 2003.
ICICI Venture has multiple exposure in the life sciences business. Its investment portfolio includes Arch Pharmalabs, Malladi Drugs, Bharat Biotech, I-Ven Pharma, RFCL, Metropolis, Perlecan, Avesthagen, Biocon, Medicorp and Intas Pharma.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment